It's interesting how a company can disclosure to market to avoid...

It's interesting how a company can disclosure to market to avoid diluting the holdings of key shareholders. We have been told historically UBI would receive 1 cent per strip from LifeScan for its blood glucose technology whereas this update tells us it's 1.25 cents for the first 500 million and 0.75 cents thereafter which works out closer to 0.83 cents than the 1 cent the company has been disclosing since listing.

And what about the juicy buyout clause LifeScan have , whereby it appears they will only pay around 2 to 2.5 times their annual royalty to extinguish their quarterly strip royalties all together.

The price reaction yesterday combined with price reductions by broker suggests Directors were clearly in possession of price sensitive information ever since IPO.